Study of KJ015 for HER2-positive solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This trial tests an experimental drug (KJ015) for people with solid tumors that have a protein called HER2. It’s for patients whose cancer has continued to grow despite previous treatments, and who are relatively well overall.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must be HER2-positive (a specific protein found on some cancer cells).
- Your cancer must have gotten worse while on your last treatment (radiographically confirmed).
- You must be at least 18 years old and have a life expectancy of at least 3 months.
- Your overall health (ECOG score) should be 0, 1, or 2 — meaning you are up and about at least half the day.
- You cannot have cancer that has spread to your brain or spinal cord, or have had certain heart or blood vessel problems.
- You cannot be pregnant or breastfeeding, and you must not have had a very high total amount of a certain chemotherapy called anthracycline.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests IKS014 to see how safe it is and how well it works in advanced solid tumors that have HER2. You may be eligible if your tumor is HER2-positive (including certain “low HER2” types) and your body’s blood counts and organ function are strong enough.
This trial compares a new experimental drug, JSKN003, to standard treatments chosen by your doctor for advanced breast cancer that tests as HER2-low (IHC 1+ or 2+ but not amplified). It's for people whose cancer has spread or can't be removed and who have already had one or two lines of chemotherapy.
This trial tests an investigational drug called JSKN033 (given as an injection) for advanced or metastatic non-small cell lung cancer. It aims to see if the drug is safe and effective. Depending on whether you have had prior treatment, you may need a HER2 mutation or HER2 expression in your tumor.
This trial tests a new combination drug (JSKN016) for people with HER2-negative breast cancer that has spread or cannot be removed. It is for those who have not yet had advanced-stage treatment (except hormone therapy) and may offer a new option.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
This trial compares a new targeted therapy (JSKN003) against Kadcyla (T-DM1) for people with HER2-positive breast cancer that has advanced or spread. Both drugs work by attaching a chemotherapy directly to HER2-positive cancer cells, and the study aims to see if the new drug works better or has fewer side effects.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.